Description
Lucentis Solution for Injections 10 mg/ml. 0.23 ml. (2 needles)
Ingredients
- Lucentis contains the active ingredient Ranibizumab at a concentration of 10 mg/ml.
Dosage
- Lucentis is administered via intravitreal injection.
- The usual dose is 0.5 mg (0.05 ml) once a month.
Indications
- Lucentis is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Contraindications
- Lucentis is contraindicated in patients with ocular or periocular infections.
Directions
- Lucentis should be administered by a healthcare professional as an intravitreal injection.
- Patients should be monitored for signs of endophthalmitis.
Scientific Evidence
- Studies have shown the efficacy of Lucentis in improving visual acuity and reducing retinal thickness in patients with neovascular AMD.
- Clinical trials have demonstrated its superiority over photodynamic therapy and placebo in the treatment of this condition.
Additional Information
- Inform patients about potential risks associated with intravitreal injections, including retinal detachment and cataract formation.
- Regular follow-up appointments are crucial to monitor the response to treatment and detect any adverse effects early.
Lucentis works by inhibiting vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the eye, thereby improving retinal function and visual outcomes.
Clinical trials have shown that Lucentis is non-inferior to Bevacizumab in terms of visual acuity outcomes in patients with neovascular AMD.
